Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5164 - The _2-microgloulin Is Associated with the Prognosis in Patients with Peripheral T-Cell Lymphoma, Not Otherwise Specified

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Topics

Tumour Site

Lymphomas

Presenters

Byeong Seok Sohn

Citation

Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286

Authors

B.S. Sohn1, S. Lim2, J. Kim3, D.H. Yoon3, S. Kim3, J. Huh3, S. Park1, Y.J. Yuh1, C. Suh3

Author affiliations

  • 1 Internal Medicine, Inje University Sanggye Paik Hospital, 13757 - Seoul/KR
  • 2 Internal Medicine, Inje University Haeundae Paik Hospital, 48108 - Busan/KR
  • 3 Oncology, Asan Medical Center, University of Ulsan College of Medicine, 05505 - Seoul/KR
More

Resources

Abstract 5164

Background

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of tumors and subdivided into specified and not otherwise specified (NOS) types. Clinically, the International Prognostic Index (IPI), Prognostic Index for T-cell lymphoma, and Bologna score have been the prognostic model to discriminate the prognosis of patients with PTCL-NOS. However, no simple prognostic marker has been satisfactory in predicting treatment outcomes in patients with PTCL-NOS.

Methods

From Sep 2005 to Aug 2016, we identified 94 patients diagnosed with PTCL-NOS initially treated with CHOP or CHOP-like regimens. Event-free survival (EFS) was calculated from the date of diagnosis to the date of disease progression, treatment failure, relapse, or death from any cause. Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause. The cut-off of serum β2-microgloulin (B2MG) was defined as > 3.2 mg/L.

Results

Among 94 patients, 41 (43.6%) patients showed B2MG > 3.2 mg/L, 37 (39.4%) patients showed B symptoms. According to IPI scores, 19 (20.2%) patients belonged to the low risk group (L), 25 (26.6%) to the low-intermediate (LI), 29 (30.9%) to the high-intermediate (HI), and 21 (22.3%) to the high (H). Complete response (CR), EFS, and OS were associated with B2MG, B symptoms, performance status, lactate dehydrogenase, extranodal involvement, Ann Arbor stage, and IPI risk group in univariate analysis. After multivariate analysis, B2MG was associated with CR (> 3.2 mg/L vs. ≤3.2 mg/L, odd ratio [OR]: 4.053, 95% confidence interval [CI]: 1.314–12.503, P = 0.015), EFS (hazard ratio [HR]: 1.721, 95% CI: 1.026–2.887, P = 0.040), but OS (HR: 1.449, 95% CI: 0.803–2.615, P = 0.218). IPI risk group was associated with CR (L/LI vs. HI/H, P = 0.022), EFS (P < 0.001), and OS (P < 0.001). In 50 patients of HI/H risk group, B2MG showed association with CR (OR: 5.464, 95% CI: 1.256–23.774, P = 0.024), EFS (HR: 2.160, 95% CI: 1.095–4.260, P = 0.026), and OS (HR: 2.158, 95% CI: 0.979–4.759, P = 0.057).

Conclusions

B2MG could be a simple prognostic factor for the patients with PTCL-NOS. B2MG > 3.2 mg/L was associated with worse prognosis of patients with PTCL-NOS, especially in HI/H risk group. The larger scaled study is warranted to confirm our result.

Clinical trial identification

Legal entity responsible for the study

Byeong Seok Sohn.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.